Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.75% | 39.89% | 45.24% | 40.58% | 20.78% |
| Total Depreciation and Amortization | -26.19% | -40.52% | -77.44% | -64.09% | -52.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -222.04% | -74.75% | -40.85% | -65.67% | 50.65% |
| Change in Net Operating Assets | 117.20% | 211.40% | -113.36% | -118.51% | -121.16% |
| Cash from Operations | 8.32% | 52.18% | -509.98% | -312,233.33% | -1,082.94% |
| Capital Expenditure | 90.94% | 93.71% | 95.28% | 96.89% | 66.75% |
| Sale of Property, Plant, and Equipment | -101.12% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 210.17% | 173.40% | 40.00% | -317.23% | -269.63% |
| Cash from Investing | 209.33% | 170.60% | 44.92% | -336.87% | -280.33% |
| Total Debt Issued | -11.11% | -- | -227.45% | -124.31% | -127.73% |
| Total Debt Repaid | -314.02% | -- | 156.67% | 148.81% | 141.07% |
| Issuance of Common Stock | 137.50% | -- | -- | -- | -46.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -641.90% | -- | 150.66% | 196.39% | 225.00% |
| Foreign Exchange rate Adjustments | 282.14% | -201.49% | -84.62% | -110.35% | 94.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.88% | 83.57% | -2,039.01% | -547.37% | -485.84% |